Edwards Lifesciences Co. (NYSE:EW) Receives Average Rating of “Hold” from Analysts

Shares of Edwards Lifesciences Co. (NYSE:EW) have received a consensus rating of “Hold” from the twenty-six brokerages that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, thirteen have issued a hold recommendation and twelve have given a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $79.95.

Several analysts have recently commented on the stock. Barclays raised their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Piper Sandler raised their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th. Canaccord Genuity Group upped their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Finally, Evercore ISI dropped their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th.

Insider Activity

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now directly owns 60,372 shares in the company, valued at $4,613,628.24. This represents a 8.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 51,303 shares of company stock valued at $3,715,776 in the last three months. Corporate insiders own 1.29% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Fairtree Asset Management Pty Ltd acquired a new position in shares of Edwards Lifesciences during the fourth quarter valued at $1,076,000. NorthCrest Asset Manangement LLC acquired a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $212,000. PKO Investment Management Joint Stock Co bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth $592,000. Probity Advisors Inc. acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $295,000. Finally, Cim LLC increased its position in shares of Edwards Lifesciences by 1.2% in the fourth quarter. Cim LLC now owns 189,399 shares of the medical research company’s stock worth $14,021,000 after acquiring an additional 2,337 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $71.43 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences has a 12 month low of $58.93 and a 12 month high of $96.12. The business’s fifty day moving average price is $71.43 and its 200 day moving average price is $70.42. The firm has a market capitalization of $41.99 billion, a PE ratio of 10.25, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, sell-side analysts anticipate that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.